Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma.
Drugs
January 2025
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Liposomal irinotecan (Onivyde), also known as liposomal pegylated irinotecan, has been developed with the intent of maximising anti-tumour efficacy and minimising drug-related toxicities compared with conventional formulations of this topoisomerase 1 inhibitor. In combination with fluorouracil, leucovorin and oxaliplatin (NALIRIFOX), liposomal irinotecan is approved in the USA and the EU for first-line therapy of eligible patients with metastatic pancreatic adenocarcinoma. In a phase III clinical trial, NALIRIFOX significantly improved overall survival (OS) and progression free survival (PFS) compared with gemcitabine plus nanoparticle albumin bound paclitaxel (nab-paclitaxel) as first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
View Article and Find Full Text PDFComparison of RT-qPCR With Branched DNA to Quantify a Lipid Nanoparticle-Encapsulated mRNA Therapeutic in Serum and Liver Tissue Samples From Nonclinical PK Studies.
AAPS J
January 2025
Moderna, Inc., Cambridge, Massachusetts, USA.
While the branched DNA (bDNA) assay is an established bioanalytical method for measurement of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) pharmacokinetic parameters, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) has been considered as an alternative platform. RT-qPCR and bDNA platforms were compared for sensitivity, specificity, correlation, and overall assay performance using serum and tissue samples from 2 nonclinical mouse studies of a therapeutic mRNA candidate, LNP-PAH-mRNA, which encodes for human phenylalanine hydroxylase enzyme. Pharmacokinetic parameter noncompartmental analysis was completed using Phoenix WinNonlin.
View Article and Find Full Text PDFSmart release injectable hydrogel co-loaded with liposomal combretastatin A4 and doxorubicin nanogel for local combinational drug delivery: A preclinical study.
Int J Pharm
January 2025
Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Surgical resection and postoperative adjuvant chemotherapy have enhanced the outlook for breast cancer patients. However, tumor relapse and serious side effects of chemotherapy continue to impact patients' quality of life. Designing injectable composite hydrogel made of biodegradable polymers providing sustained release of antiangiogenic and chemotherapeutic agents might play a vital role in elimination of cancer cells.
View Article and Find Full Text PDFDevelopment, Optimization, and Evaluation of Rutin-Loaded Liposomes in the Management of Rheumatoid Arthritis.
Curr Drug Deliv
January 2025
Department of Pharmaceutical Sciences, Gurugram University, Gurugram - 122018, India.
Background: Rheumatoid arthritis is a chronic autoimmune disease, progressively distinctive via cartilage destruction, auto-antibody production, severe joint pain, and synovial inflammation. Nanotechnology represents one of the utmost promising scientific technologies of the 21st century. Nanocarriers could be the key to unlocking its potential by encapsulating Rutin in targeted drug delivery systems, potentially for targeted Rheumatoid arthritis therapy.
View Article and Find Full Text PDFEmbracing Nature's Wisdom: Liposome-Mediated Amplification of Electrochemiluminescence for the Sensitive and Selective Immunoassay of Serum Amyloid A.
Anal Chem
January 2025
School of Environmental and Biological Engineering, Nanjing University of Science and Technology, Nanjing 210094, P R China.
Serum amyloid A (SAA) is a key biomarker for diagnosing inflammatory responses in diseases like influenza and COVID-19. An electrochemiluminescence (ECL) biosensor has been constructed for signal enhancement in SAA detection by encapsulating 4,4',4″,4‴-(1,3,6,8-pyrenetetrayl) tetrakis-benzoic acid (TBAPy) into liposomes. Such biomimetic encapsulation shields the biologically important membrane to avoid aggregation of TBAPy and prevents quenching.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!